[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100394888":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":51,"collaborators":25,"id":53,"slug":25,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":25,"enrollmentInfo":62,"targetDuration":25,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Medical University of Graz","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Thrombelastogram (TEG)","EXPERIMENTAL","Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE\u002Fkg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.",[13],"Procedure: thrombelastogram",{"label":15,"type":10,"description":16,"interventionNames":17},"Standard of Care (SOC)","In the SOC group, patients will receive PCC at the dose of 10 IE \u002Fkg of ideal body weight when the PT is below 50% and\u002For INR\\>1.8 and\u002For received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G\u002FL",[18],"Procedure: standard of care",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","thrombelastogram","Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE\u002Fkg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"standard of care","2\\) In the SOC group, patients will receive PCC at the dose of 10 IE \u002Fkg of ideal body weight when the PT is below 50% and\u002For INR\\>1.8 and\u002For received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G\u002FL",[15],[31],{"facility":32,"status":33,"city":34,"state":25,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Internal Medicine, Medical University of Graz","RECRUITING","Graz","8010","Austria","AT",{"type":39,"coordinates":40},"Point",[41,42],15.44197,47.06733,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Vanessa Stadlbauer, MD","CONTACT","0043316385","82282","vanessa.stadlbauer@medunigraz.at",{"type":52,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100394888",false,"NCT04421924","Periinterventional Coagulation Management of Patients Undergoing a TIPS","Optimizing Periinterventional Coagulation Management of Patients Undergoing a Transjugular Intrahepatic Portosystemic Shunt Implantation: A Prospective Randomized Cohort Study","TIPSprosp","inclusion criteria\n\n* Liver cirrhosis\n* \\>18 years\n* Indication for TIPS implantation\n* Ability to sign informed consent exclusion criteria\n* Contraindications against TIPS implantation\n* Hepatocellular carcinoma BCLC D\n* Ongoing bleeding\n* pre-existing anticoagulant therapy at time of inclusion\n* administration of blood products within 1 week prior to the enrolment\n* Other malignancies that lead to an impaired 90-day survival\n* Inherit blood clotting disorders\n* Hepatic encephalopathy grade 3 or 4\n* any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol","ALL","18 Years",{"count":63,"type":64},39,"ESTIMATED","INTERVENTIONAL",[67],"NA","Assess whether a pre-interventional thrombelastography guided algorithm for assessing and correction of coagulation status in cirrhotic patients is safe and effective",[70],"Liver Cirrhosis","2025-12-02",{"date":73,"type":74},"2025-12-09","ACTUAL",{"date":76,"type":74},"2020-05-27",{"date":78,"type":64},"2027-05",{"name":5,"class":6},1]